Paradigm Biopharmaceuticals Ltd. raised AU$16 million (US$10.31 million) in a placement that will allow the company to start a global phase III trial with its lead product, Zilosul (injectable ...
Kinetics Paradigm Fund earns an Above Average Process Pillar rating. The primary contributor to the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm ...